Identification of BCR-ABL kinase domain mutations. Tyrosine kinase inhibitor therapy in CML patients may develop Gleevec resistance.
Additional Test Information
EDTA Bone Marrow (lavender top) or EDTA Whole Blood (lavender top)
Additional Sample Requirements
Sample must be received within 48 hours of collection. Indicate on specimen tube and requisition whether sample is whole blood or bone marrow.
3-5 ml EDTA Bone Marrow (lavender top) or 10 ml EDTA Whole Blood (lavender top)